Good News for Undervalued Sanofi

In the large Odyssey study, Praluent statistically significantly reduced the risk of MACE (the primary endpoint based on a composite of heart attack, ischemic stroke, death from coronary heart disease, or unstable angina requiring hospitalization) by 15% (similar to the benefit seen from Amgen’s Repatha in a different outcomes study of slightly less sick patients) with a strong p-value of 0.0003. The study also showed that Praluent caused a reduction in all-cause death. In the patient population with LDL cholesterol above 100 mg/dL, the reduction in all-cause death was an impressive 29%. Importantly, no significant safety signals were seen across the study of almost 19,000 patients. At the American College of Cardiology meeting, where the data was presented, 62% of the doctors surveyed stated they would change their prescribing habits because of the data.

Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.